Comparative Pharmacology
Head-to-head clinical analysis: KLONOPIN RAPIDLY DISINTEGRATING versus MIDOZALAM HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KLONOPIN RAPIDLY DISINTEGRATING versus MIDOZALAM HYDROCHLORIDE.
KLONOPIN RAPIDLY DISINTEGRATING vs MIDOZALAM HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine; enhances GABA-A receptor activity by increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and inhibition.
Midazolam hydrochloride is a benzodiazepine that enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, resulting in increased chloride ion conductance, neuronal hyperpolarization, and inhibition of neuronal transmission. This produces sedative, anxiolytic, amnestic, and anticonvulsant effects.
0.5 mg to 2 mg orally twice daily for anxiety; 0.5 mg to 1 mg orally three times daily for panic disorder. Maximum dose: 4 mg/day for panic disorder.
2.5-10 mg IV bolus for induction; 0.05-0.2 mg/kg/h IV infusion for sedation. IM: 0.07-0.08 mg/kg (max 5 mg) 30-60 min pre-procedure.
None Documented
None Documented
Terminal half-life 30-40 hours (range 19-60 h) in adults; accumulation occurs with repeated dosing, steady-state reached in 5-7 days.
Terminal elimination half-life: 1.5-3 hours in healthy adults; prolonged in elderly (up to 6 hours), obesity, hepatic cirrhosis (up to 20 hours), and congestive heart failure.
Renal (60-80% as metabolites, mainly glucuronide conjugates; <2% as unchanged drug). Biliary/fecal excretion accounts for ~10-20%.
Renal excretion of metabolites (approximately 90% as glucuronide conjugates, with less than 1% unchanged drug) and biliary/fecal excretion (approximately 5-10%).
Category C
Category C
Benzodiazepine
Benzodiazepine